Endocannabinoidomics: “Omics” Approaches Applied to Endocannabinoids and Endocannabinoid-Like Mediators

Piscitelli, Fabiana

doi:10.1016/b978-0-12-420126-2.00009-2

Cited by 4 publications

(2 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The endocannabinoidome encompasses structurally-related lipid mediators ( Di Marzo and Wang, 2014 ; Piscitelli, 2015 ) involved in diverse biological mechanisms, with broad modulatory effects extending beyond the traditional endocannabinoid signaling pathways mediated by anandamide and 2-AG ( Pacher, 2006 ; Pacher and Kunos, 2013 ; Pacher et al, 2020 ). Given that endocannabinoids play a crucial role in brain development, neural plasticity and function ( Viveros et al, 2007 ), it is expected that changes in their concentrations would be associated with specific behavioral manifestations.…”

Section: Discussionmentioning

confidence: 99%

Endocannabinoid basis of personality—Insights from animal model of social behavior

Kogan,

Begmatova,

Vinnikova

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Rationale: The endocannabinoid system is known to be involved in learning, memory, emotional processing and regulation of personality patterns. Here we assessed the endocannabinoid profile in the brains of mice with strong characteristics of social dominance and submissiveness.Methods: A lipidomics approach was employed to assess the endocannabinoidome in the brains of Dominant (Dom) and Submissive (Sub) mice. The endocannabinoid showing the greatest difference in concentration in the brain between the groups, docosatetraenoyl ethanolamine (DEA), was synthesized, and its effects on the physiological and behavioral responses of Dom and Sub mice were evaluated. mRNA expression of the endocannabinoid receptors and enzymes involved in PUFA biosynthesis was assessed using qRT-PCR.Results: Targeted LC/MS analysis revealed that long-chain polyunsaturated ethanolamides including arachidonoyl ethanolamide (AEA), DEA, docosatrienoyl ethanolamide (DTEA), eicosatrienoyl ethanolamide (ETEA), eicosapentaenoyl ethanolamide (EPEA) and docosahexaenoyl ethanolamide (DHEA) were higher in the Sub compared with the Dom mice. Untargeted LC/MS analysis showed that the parent fatty acids, docosatetraenoic (DA) and eicosapentaenoic (EPA), were higher in Sub vs. Dom. Gene expression analysis revealed increased mRNA expression of genes encoding the desaturase FADS2 and the elongase ELOVL5 in Sub mice compared with Dom mice. Acute DEA administration at the dose of 15 mg/kg produced antinociceptive and locomotion-inducing effects in Sub mice, but not in Dom mice. Subchronic treatment with DEA at the dose of 5 mg/kg augmented dominant behavior in wild-type ICR and Dom mice but not in Sub mice.Conclusion: This study suggests that the endocannabinoid system may play a role in the regulation of dominance and submissiveness, functional elements of social behavior and personality. While currently we have only scratched the surface, understanding the role of the endocannabinoid system in personality may help in revealing the mechanisms underlying the etiopathology of psychiatric disorders.

show abstract

Section: Discussionmentioning

confidence: 99%

Endocannabinoid basis of personality—Insights from animal model of social behavior

Kogan,

Begmatova,

Vinnikova

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…It has been repeatedly found in dozens of vegetable and animal food sources (in nanogram per gram level), from soy to carrots and from eggs to beef [ 39 , 46 ]. Moreover, PEA levels have also been detected in virtually any tissue and body fluid [ 46 , 51 ], where it is enzymatically produced “on demand” in response to actual or potential damage and enzymatically cleaved when it has served its purpose [ 51 , 52 , 113 , 114 , 115 ].…”

Section: Endogenous Pea and Pain Modulationmentioning

confidence: 99%

Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?

Rocca

Gamba²

2021

Animals

View full text Add to dashboard Cite

The management of chronic pain is an integral challenge of small animal veterinary practitioners. Multiple pharmacological agents are usually employed to treat maladaptive pain including opiates, non-steroidal anti-inflammatory drugs, anticonvulsants, antidepressants, and others. In order to limit adverse effects and tolerance development, they are often combined with non-pharmacologic measures such as acupuncture and dietary interventions. Accumulating evidence suggests that non-neuronal cells such as mast cells and microglia play active roles in the pathogenesis of maladaptive pain. Accordingly, these cells are currently viewed as potential new targets for managing chronic pain. Palmitoylethanolamide is an endocannabinoid-like compound found in several food sources and considered a body’s own analgesic. The receptor-dependent control of non-neuronal cells mediates the pain-relieving effect of palmitoylethanolamide. Accumulating evidence shows the anti-hyperalgesic effect of supplemented palmitoylethanolamide, especially in the micronized and co-micronized formulations (i.e., micro-palmitoylethanolamide), which allow for higher bioavailability. In the present paper, the role of non-neuronal cells in pain signaling is discussed and a large number of studies on the effect of palmitoylethanolamide in inflammatory and neuropathic chronic pain are reviewed. Overall, available evidence suggests that there is place for micro-palmitoylethanolamide in the dietary management of chronic pain in dogs and cats.

show abstract

New approaches and challenges to targeting the endocannabinoid system

Marzo

2018

Nat Rev Drug Discov

389

396

View full text Add to dashboard Cite

The endocannabinoid signalling system was discovered because receptors in this system are the targets of compounds present in psychotropic preparations of Cannabis sativa. The search for new therapeutics that target endocannabinoid signalling is both challenging and potentially rewarding, as endocannabinoids are implicated in numerous physiological and pathological processes. Hundreds of mediators chemically related to the endocannabinoids, often with similar metabolic pathways but different targets, have complicated the development of inhibitors of endocannabinoid metabolic enzymes but have also stimulated the rational design of multi-target drugs. Meanwhile, drugs based on botanical cannabinoids have come to the clinical forefront, synthetic agonists designed to bind cannabinoid receptor 1 with very high affinity have become a societal threat and the gut microbiome has been found to signal in part through the endocannabinoid network. The current development of drugs that alter endocannabinoid signalling and how this complex system could be pharmacologically manipulated in the future are described in this Opinion article.

show abstract

Endocannabinoidomics: “Omics” Approaches Applied to Endocannabinoids and Endocannabinoid-Like Mediators

Cited by 4 publications

References 62 publications

Endocannabinoid basis of personality—Insights from animal model of social behavior

Endocannabinoid basis of personality—Insights from animal model of social behavior

Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide?

New approaches and challenges to targeting the endocannabinoid system

Contact Info

Product

Resources

About